Vivia's main differentiating factor is its ExviTech (ex-vivo Technology) Technological Platform which allows for the ex-vivo analysis (in a standard biological sample recently extracted and fresh of the effect of thousands of drugs or combinations in less than 48 hours. By comparison, in the same sample in fresh condition, the present technology allows for the systematic and routine analysis of only 10 to 100 drugs per sample.
The ExviTech technological platform essentially consists in automating the most sophisticated flow cytometry instruments, which is the core technology of our platform. Flow cytometry is a technology that has existed for more than 20 years. It is routinely used in the large majority of analyses of fresh samples of blood cells or bone marrow, mainly for diagnostic use. It is therefore a cross-referenced, validated and reliable technique. In fact, it is commonly used in diagnosing the kind of hematological cancers that Vivia studies.
This validation of the core technology used by the ExviTech platform is crucial, since escalating a highly validated technique substantially increases the probability of the project’s success.
The ExviTech technological platform is a complete platform that integrates various concatenated components to attain the necessary global performance:
The ExviTech technological platform allows for the simultaneous measuring of 100 independent parameters per cell, and is capable of analyzing tens of thousands of blood cells per second, framed in the scientific field of “High Content Screening" (HCS), where the number of components evaluated is high and the contents evaluated per component is even greater.
The result of evaluating daily thousands of drugs at this level implies analyzing thousands of data daily, to which end ActivityBase, the greatest capacity data base for these screening activities, has been incorporated and special bioinformatic analysis tools have been developed.
All of the above makes ExviTech a highly innovative technological platform. It is the only one in the world capable of analyzing the effect of thousands of drugs in a given patient's standard sample in fresh condition, within 24/48 hours of extraction.
Lastly, it is important to point out that ExviTech is not an experimental technique but a validated integrated platform of industrial drug screening. ExviTech has been routinely used in the last three years for screening thousands of compounds daily. Now, through Vivia, the platform's full potential is placed at the service of the study of low prevalence illnesses.